α4β1 Search Results


N/A
This product is a recombinant monoclonal antibody expressed from HEK293 cells.
  Buy from Supplier


90
Bachem α4β1 integrin antagonist 4- ((2methylphenyl)aminocarbonyl)aminophenyl)acetyl-ldvp (phldvp) 7
α4β1 Integrin Antagonist 4 ((2methylphenyl)aminocarbonyl)aminophenyl)acetyl Ldvp (Phldvp) 7, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B14%CE%B21/%CE%B14%CE%B21+specific+peptide++1+adamantaneacetyl+cys+gly+arg+gly+asp+ser+pro+cys+oh/10__1161_slash_01__res__0000115555__05668__93-400-1-11
Average 90 stars, based on 1 article reviews
α4β1 integrin antagonist 4- ((2methylphenyl)aminocarbonyl)aminophenyl)acetyl-ldvp (phldvp) 7 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
InnoPep Inc cyclic peptide inhibitor of integrin α4β1 conjugated to methrol
Cyclic Peptide Inhibitor Of Integrin α4β1 Conjugated To Methrol, supplied by InnoPep Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B14%CE%B21/cyclic+peptide+inhibitor+of+integrin+%CE%B14%CE%B21+conjugated+to+methrol/pmc08093802-120-1-17
Average 90 stars, based on 1 article reviews
cyclic peptide inhibitor of integrin α4β1 conjugated to methrol - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Becton Dickinson α4β1 integrin
α4β1 Integrin, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B14%CE%B21/fitc+conjugated+anti+%CE%B14%CE%B21/pmc03050662-148-10-12
Average 90 stars, based on 1 article reviews
α4β1 integrin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Johns Hopkins HealthCare α4β1 integrin
α4β1 Integrin, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B14%CE%B21/%CE%B14%CE%B21+integrin/pmc03183010__supp_22__19__3555_2005_ASCB_Abstracts-12192-27-20
Average 90 stars, based on 1 article reviews
α4β1 integrin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
AAPPTec Inc integrin α4β1-binding redv peptide (g redv gc, >90% purity)
A) Schematic showing PEG-MAL hydrogels functionalized with REDV or RGD peptides and embedded with naïve B cells and 40LB stromal cells in the presence of soluble IL-4 cytokine. B) Phase contrast images show qualitative distribution of B cells in 2D co-cultures (left) and 3D immune tissues (right). C) Confocal images of 40LB stromal cells and B cells in 3D immune tissues. D) Role of <t>integrin</t> ligand and 40LB density on GC induction. Scatter plot represents median fluorescent intensity of GL7 in GL7+CD19+ GC B cells as a function of integrin ligand VCAM-1 (REDV) and vitronectin (RGD), and 40LB cell density (20,000 vs. 40,000 40LB cells per 10 μL hydrogel). N = 6; Mean ± S.E.M; **P < 0.005, *P < 0.05; 2-way ANOVA with Bonferroni correction. E) Effect of blocking CD40L on GC induction. Scatter plot represents percentage GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with RGD in the presence of anti-CD40L antibody added at various time points in culture. N = 5; Mean ± S.E.M; ***P < 0.0001; 1-way ANOVA with Tukey’s post-hoc correction. F) Temporal dependency of integrin ligand interaction on GC B cells. Relative percentages of cells were quantified for GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with either REDV (blue) or RGD (red) in the presence of <t>anti-α4β1</t> antibody or Cilengitide anti-αvβ3 peptide) added at various time points in culture. GL7+ CD19 + percentage was normalized to the no inhibitor treatment. N = 6; Mean ± S.E.M; Statistical significance was tested based on p < 0.05 using 2-way ANOVA with Bonferroni correction. ***P < 0.0001, **P < 0.001. Control: No inhibitor. G) The percentage of CD83 + CD19 + B cells as a function of hydrogel volume. Immune tissues, encapsulating 40,000 B cells and 40,000 40LB cells, were cultured for 4 days in media containing 10 ng/mL IL-4. H) CD83 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. I) CD83 + CD19 + and CD83−CD19 + B cells as a function of hydrogel volume, cultured for 4 days. J) CXCR4 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. K-L) GL7 expression in GL7+ CD19+ GC-like B cell population and the percentage of CD83 + CD19 + GC B as a function of B cell seeding density in 10 μL PEG-MAL hydrogel, cultured for 4 days. ***P < 0.0001, **P < 0.001, *P < 0.05; 1 Way ANOVA with Tukey’s Test. Values are shown as mean ± SEM (n = 5). M-N) CD83 and CXCR4 expression level based on median fluorescence intensity (MFI) in CD83 + CD19 + B cell population following 4-day culture in RGD hydrogel with the addition of anti-CD40L antibody to block CD40 signaling at day 0 (D0) and day 2 (D2). Control group was prepared with no blocking performed (No Block). Statistical significance was tested based on p < 0.05 using 1-way ANOVA with Tukey’s test (N = 5; Mean ± S.E.M). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Integrin α4β1 Binding Redv Peptide (G Redv Gc, >90% Purity), supplied by AAPPTec Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B14%CE%B21/integrin+%CE%B14%CE%B21+binding+redv++nh2+g+redv+gc+cooh+/pmc06355359-110-16-40
Average 90 stars, based on 1 article reviews
integrin α4β1-binding redv peptide (g redv gc, >90% purity) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Schmid GmbH α4β1 integrin
A) Schematic showing PEG-MAL hydrogels functionalized with REDV or RGD peptides and embedded with naïve B cells and 40LB stromal cells in the presence of soluble IL-4 cytokine. B) Phase contrast images show qualitative distribution of B cells in 2D co-cultures (left) and 3D immune tissues (right). C) Confocal images of 40LB stromal cells and B cells in 3D immune tissues. D) Role of <t>integrin</t> ligand and 40LB density on GC induction. Scatter plot represents median fluorescent intensity of GL7 in GL7+CD19+ GC B cells as a function of integrin ligand VCAM-1 (REDV) and vitronectin (RGD), and 40LB cell density (20,000 vs. 40,000 40LB cells per 10 μL hydrogel). N = 6; Mean ± S.E.M; **P < 0.005, *P < 0.05; 2-way ANOVA with Bonferroni correction. E) Effect of blocking CD40L on GC induction. Scatter plot represents percentage GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with RGD in the presence of anti-CD40L antibody added at various time points in culture. N = 5; Mean ± S.E.M; ***P < 0.0001; 1-way ANOVA with Tukey’s post-hoc correction. F) Temporal dependency of integrin ligand interaction on GC B cells. Relative percentages of cells were quantified for GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with either REDV (blue) or RGD (red) in the presence of <t>anti-α4β1</t> antibody or Cilengitide anti-αvβ3 peptide) added at various time points in culture. GL7+ CD19 + percentage was normalized to the no inhibitor treatment. N = 6; Mean ± S.E.M; Statistical significance was tested based on p < 0.05 using 2-way ANOVA with Bonferroni correction. ***P < 0.0001, **P < 0.001. Control: No inhibitor. G) The percentage of CD83 + CD19 + B cells as a function of hydrogel volume. Immune tissues, encapsulating 40,000 B cells and 40,000 40LB cells, were cultured for 4 days in media containing 10 ng/mL IL-4. H) CD83 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. I) CD83 + CD19 + and CD83−CD19 + B cells as a function of hydrogel volume, cultured for 4 days. J) CXCR4 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. K-L) GL7 expression in GL7+ CD19+ GC-like B cell population and the percentage of CD83 + CD19 + GC B as a function of B cell seeding density in 10 μL PEG-MAL hydrogel, cultured for 4 days. ***P < 0.0001, **P < 0.001, *P < 0.05; 1 Way ANOVA with Tukey’s Test. Values are shown as mean ± SEM (n = 5). M-N) CD83 and CXCR4 expression level based on median fluorescence intensity (MFI) in CD83 + CD19 + B cell population following 4-day culture in RGD hydrogel with the addition of anti-CD40L antibody to block CD40 signaling at day 0 (D0) and day 2 (D2). Control group was prepared with no blocking performed (No Block). Statistical significance was tested based on p < 0.05 using 1-way ANOVA with Tukey’s test (N = 5; Mean ± S.E.M). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
α4β1 Integrin, supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B14%CE%B21/%CE%B14%CE%B21+integrin/pm37245545-270-2-30
Average 90 stars, based on 1 article reviews
α4β1 integrin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

91
Bio X Cell vla 4 antibody
A) Schematic showing PEG-MAL hydrogels functionalized with REDV or RGD peptides and embedded with naïve B cells and 40LB stromal cells in the presence of soluble IL-4 cytokine. B) Phase contrast images show qualitative distribution of B cells in 2D co-cultures (left) and 3D immune tissues (right). C) Confocal images of 40LB stromal cells and B cells in 3D immune tissues. D) Role of <t>integrin</t> ligand and 40LB density on GC induction. Scatter plot represents median fluorescent intensity of GL7 in GL7+CD19+ GC B cells as a function of integrin ligand VCAM-1 (REDV) and vitronectin (RGD), and 40LB cell density (20,000 vs. 40,000 40LB cells per 10 μL hydrogel). N = 6; Mean ± S.E.M; **P < 0.005, *P < 0.05; 2-way ANOVA with Bonferroni correction. E) Effect of blocking CD40L on GC induction. Scatter plot represents percentage GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with RGD in the presence of anti-CD40L antibody added at various time points in culture. N = 5; Mean ± S.E.M; ***P < 0.0001; 1-way ANOVA with Tukey’s post-hoc correction. F) Temporal dependency of integrin ligand interaction on GC B cells. Relative percentages of cells were quantified for GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with either REDV (blue) or RGD (red) in the presence of <t>anti-α4β1</t> antibody or Cilengitide anti-αvβ3 peptide) added at various time points in culture. GL7+ CD19 + percentage was normalized to the no inhibitor treatment. N = 6; Mean ± S.E.M; Statistical significance was tested based on p < 0.05 using 2-way ANOVA with Bonferroni correction. ***P < 0.0001, **P < 0.001. Control: No inhibitor. G) The percentage of CD83 + CD19 + B cells as a function of hydrogel volume. Immune tissues, encapsulating 40,000 B cells and 40,000 40LB cells, were cultured for 4 days in media containing 10 ng/mL IL-4. H) CD83 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. I) CD83 + CD19 + and CD83−CD19 + B cells as a function of hydrogel volume, cultured for 4 days. J) CXCR4 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. K-L) GL7 expression in GL7+ CD19+ GC-like B cell population and the percentage of CD83 + CD19 + GC B as a function of B cell seeding density in 10 μL PEG-MAL hydrogel, cultured for 4 days. ***P < 0.0001, **P < 0.001, *P < 0.05; 1 Way ANOVA with Tukey’s Test. Values are shown as mean ± SEM (n = 5). M-N) CD83 and CXCR4 expression level based on median fluorescence intensity (MFI) in CD83 + CD19 + B cell population following 4-day culture in RGD hydrogel with the addition of anti-CD40L antibody to block CD40 signaling at day 0 (D0) and day 2 (D2). Control group was prepared with no blocking performed (No Block). Statistical significance was tested based on p < 0.05 using 1-way ANOVA with Tukey’s test (N = 5; Mean ± S.E.M). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Vla 4 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B14%CE%B21/InVivoSIM+anti-human+integrin+%CE%B14%CE%B21/pm37730993-488-11-13
Average 91 stars, based on 1 article reviews
vla 4 antibody - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier

86
Agenus Inc anti anti vla 4 antibody antibody
A) Schematic showing PEG-MAL hydrogels functionalized with REDV or RGD peptides and embedded with naïve B cells and 40LB stromal cells in the presence of soluble IL-4 cytokine. B) Phase contrast images show qualitative distribution of B cells in 2D co-cultures (left) and 3D immune tissues (right). C) Confocal images of 40LB stromal cells and B cells in 3D immune tissues. D) Role of <t>integrin</t> ligand and 40LB density on GC induction. Scatter plot represents median fluorescent intensity of GL7 in GL7+CD19+ GC B cells as a function of integrin ligand VCAM-1 (REDV) and vitronectin (RGD), and 40LB cell density (20,000 vs. 40,000 40LB cells per 10 μL hydrogel). N = 6; Mean ± S.E.M; **P < 0.005, *P < 0.05; 2-way ANOVA with Bonferroni correction. E) Effect of blocking CD40L on GC induction. Scatter plot represents percentage GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with RGD in the presence of anti-CD40L antibody added at various time points in culture. N = 5; Mean ± S.E.M; ***P < 0.0001; 1-way ANOVA with Tukey’s post-hoc correction. F) Temporal dependency of integrin ligand interaction on GC B cells. Relative percentages of cells were quantified for GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with either REDV (blue) or RGD (red) in the presence of <t>anti-α4β1</t> antibody or Cilengitide anti-αvβ3 peptide) added at various time points in culture. GL7+ CD19 + percentage was normalized to the no inhibitor treatment. N = 6; Mean ± S.E.M; Statistical significance was tested based on p < 0.05 using 2-way ANOVA with Bonferroni correction. ***P < 0.0001, **P < 0.001. Control: No inhibitor. G) The percentage of CD83 + CD19 + B cells as a function of hydrogel volume. Immune tissues, encapsulating 40,000 B cells and 40,000 40LB cells, were cultured for 4 days in media containing 10 ng/mL IL-4. H) CD83 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. I) CD83 + CD19 + and CD83−CD19 + B cells as a function of hydrogel volume, cultured for 4 days. J) CXCR4 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. K-L) GL7 expression in GL7+ CD19+ GC-like B cell population and the percentage of CD83 + CD19 + GC B as a function of B cell seeding density in 10 μL PEG-MAL hydrogel, cultured for 4 days. ***P < 0.0001, **P < 0.001, *P < 0.05; 1 Way ANOVA with Tukey’s Test. Values are shown as mean ± SEM (n = 5). M-N) CD83 and CXCR4 expression level based on median fluorescence intensity (MFI) in CD83 + CD19 + B cell population following 4-day culture in RGD hydrogel with the addition of anti-CD40L antibody to block CD40 signaling at day 0 (D0) and day 2 (D2). Control group was prepared with no blocking performed (No Block). Statistical significance was tested based on p < 0.05 using 1-way ANOVA with Tukey’s test (N = 5; Mean ± S.E.M). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Anti Anti Vla 4 Antibody Antibody, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B14%CE%B21/4+integrin+nps+targeted+vla+%CE%B14%CE%B21/us12385925-562-1-1
Average 86 stars, based on 1 article reviews
anti anti vla 4 antibody antibody - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

90
Ayerst Laboratories wyeth-ayerst phenylalanine-based α4β1/vcam antagonists
A) Schematic showing PEG-MAL hydrogels functionalized with REDV or RGD peptides and embedded with naïve B cells and 40LB stromal cells in the presence of soluble IL-4 cytokine. B) Phase contrast images show qualitative distribution of B cells in 2D co-cultures (left) and 3D immune tissues (right). C) Confocal images of 40LB stromal cells and B cells in 3D immune tissues. D) Role of <t>integrin</t> ligand and 40LB density on GC induction. Scatter plot represents median fluorescent intensity of GL7 in GL7+CD19+ GC B cells as a function of integrin ligand VCAM-1 (REDV) and vitronectin (RGD), and 40LB cell density (20,000 vs. 40,000 40LB cells per 10 μL hydrogel). N = 6; Mean ± S.E.M; **P < 0.005, *P < 0.05; 2-way ANOVA with Bonferroni correction. E) Effect of blocking CD40L on GC induction. Scatter plot represents percentage GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with RGD in the presence of anti-CD40L antibody added at various time points in culture. N = 5; Mean ± S.E.M; ***P < 0.0001; 1-way ANOVA with Tukey’s post-hoc correction. F) Temporal dependency of integrin ligand interaction on GC B cells. Relative percentages of cells were quantified for GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with either REDV (blue) or RGD (red) in the presence of <t>anti-α4β1</t> antibody or Cilengitide anti-αvβ3 peptide) added at various time points in culture. GL7+ CD19 + percentage was normalized to the no inhibitor treatment. N = 6; Mean ± S.E.M; Statistical significance was tested based on p < 0.05 using 2-way ANOVA with Bonferroni correction. ***P < 0.0001, **P < 0.001. Control: No inhibitor. G) The percentage of CD83 + CD19 + B cells as a function of hydrogel volume. Immune tissues, encapsulating 40,000 B cells and 40,000 40LB cells, were cultured for 4 days in media containing 10 ng/mL IL-4. H) CD83 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. I) CD83 + CD19 + and CD83−CD19 + B cells as a function of hydrogel volume, cultured for 4 days. J) CXCR4 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. K-L) GL7 expression in GL7+ CD19+ GC-like B cell population and the percentage of CD83 + CD19 + GC B as a function of B cell seeding density in 10 μL PEG-MAL hydrogel, cultured for 4 days. ***P < 0.0001, **P < 0.001, *P < 0.05; 1 Way ANOVA with Tukey’s Test. Values are shown as mean ± SEM (n = 5). M-N) CD83 and CXCR4 expression level based on median fluorescence intensity (MFI) in CD83 + CD19 + B cell population following 4-day culture in RGD hydrogel with the addition of anti-CD40L antibody to block CD40 signaling at day 0 (D0) and day 2 (D2). Control group was prepared with no blocking performed (No Block). Statistical significance was tested based on p < 0.05 using 1-way ANOVA with Tukey’s test (N = 5; Mean ± S.E.M). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Wyeth Ayerst Phenylalanine Based α4β1/Vcam Antagonists, supplied by Ayerst Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B14%CE%B21/wyeth+ayerst+phenylalanine+based+%CE%B14%CE%B21+vcam+antagonists/pm12052218-412-5-3
Average 90 stars, based on 1 article reviews
wyeth-ayerst phenylalanine-based α4β1/vcam antagonists - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
BioTherapeutics Inc α4β1 integrin
A) Schematic showing PEG-MAL hydrogels functionalized with REDV or RGD peptides and embedded with naïve B cells and 40LB stromal cells in the presence of soluble IL-4 cytokine. B) Phase contrast images show qualitative distribution of B cells in 2D co-cultures (left) and 3D immune tissues (right). C) Confocal images of 40LB stromal cells and B cells in 3D immune tissues. D) Role of <t>integrin</t> ligand and 40LB density on GC induction. Scatter plot represents median fluorescent intensity of GL7 in GL7+CD19+ GC B cells as a function of integrin ligand VCAM-1 (REDV) and vitronectin (RGD), and 40LB cell density (20,000 vs. 40,000 40LB cells per 10 μL hydrogel). N = 6; Mean ± S.E.M; **P < 0.005, *P < 0.05; 2-way ANOVA with Bonferroni correction. E) Effect of blocking CD40L on GC induction. Scatter plot represents percentage GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with RGD in the presence of anti-CD40L antibody added at various time points in culture. N = 5; Mean ± S.E.M; ***P < 0.0001; 1-way ANOVA with Tukey’s post-hoc correction. F) Temporal dependency of integrin ligand interaction on GC B cells. Relative percentages of cells were quantified for GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with either REDV (blue) or RGD (red) in the presence of <t>anti-α4β1</t> antibody or Cilengitide anti-αvβ3 peptide) added at various time points in culture. GL7+ CD19 + percentage was normalized to the no inhibitor treatment. N = 6; Mean ± S.E.M; Statistical significance was tested based on p < 0.05 using 2-way ANOVA with Bonferroni correction. ***P < 0.0001, **P < 0.001. Control: No inhibitor. G) The percentage of CD83 + CD19 + B cells as a function of hydrogel volume. Immune tissues, encapsulating 40,000 B cells and 40,000 40LB cells, were cultured for 4 days in media containing 10 ng/mL IL-4. H) CD83 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. I) CD83 + CD19 + and CD83−CD19 + B cells as a function of hydrogel volume, cultured for 4 days. J) CXCR4 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. K-L) GL7 expression in GL7+ CD19+ GC-like B cell population and the percentage of CD83 + CD19 + GC B as a function of B cell seeding density in 10 μL PEG-MAL hydrogel, cultured for 4 days. ***P < 0.0001, **P < 0.001, *P < 0.05; 1 Way ANOVA with Tukey’s Test. Values are shown as mean ± SEM (n = 5). M-N) CD83 and CXCR4 expression level based on median fluorescence intensity (MFI) in CD83 + CD19 + B cell population following 4-day culture in RGD hydrogel with the addition of anti-CD40L antibody to block CD40 signaling at day 0 (D0) and day 2 (D2). Control group was prepared with no blocking performed (No Block). Statistical significance was tested based on p < 0.05 using 1-way ANOVA with Tukey’s test (N = 5; Mean ± S.E.M). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
α4β1 Integrin, supplied by BioTherapeutics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B14%CE%B21/%CE%B14%CE%B21+integrin/pm19038604-1-16-57
Average 90 stars, based on 1 article reviews
α4β1 integrin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


A) Schematic showing PEG-MAL hydrogels functionalized with REDV or RGD peptides and embedded with naïve B cells and 40LB stromal cells in the presence of soluble IL-4 cytokine. B) Phase contrast images show qualitative distribution of B cells in 2D co-cultures (left) and 3D immune tissues (right). C) Confocal images of 40LB stromal cells and B cells in 3D immune tissues. D) Role of integrin ligand and 40LB density on GC induction. Scatter plot represents median fluorescent intensity of GL7 in GL7+CD19+ GC B cells as a function of integrin ligand VCAM-1 (REDV) and vitronectin (RGD), and 40LB cell density (20,000 vs. 40,000 40LB cells per 10 μL hydrogel). N = 6; Mean ± S.E.M; **P < 0.005, *P < 0.05; 2-way ANOVA with Bonferroni correction. E) Effect of blocking CD40L on GC induction. Scatter plot represents percentage GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with RGD in the presence of anti-CD40L antibody added at various time points in culture. N = 5; Mean ± S.E.M; ***P < 0.0001; 1-way ANOVA with Tukey’s post-hoc correction. F) Temporal dependency of integrin ligand interaction on GC B cells. Relative percentages of cells were quantified for GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with either REDV (blue) or RGD (red) in the presence of anti-α4β1 antibody or Cilengitide anti-αvβ3 peptide) added at various time points in culture. GL7+ CD19 + percentage was normalized to the no inhibitor treatment. N = 6; Mean ± S.E.M; Statistical significance was tested based on p < 0.05 using 2-way ANOVA with Bonferroni correction. ***P < 0.0001, **P < 0.001. Control: No inhibitor. G) The percentage of CD83 + CD19 + B cells as a function of hydrogel volume. Immune tissues, encapsulating 40,000 B cells and 40,000 40LB cells, were cultured for 4 days in media containing 10 ng/mL IL-4. H) CD83 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. I) CD83 + CD19 + and CD83−CD19 + B cells as a function of hydrogel volume, cultured for 4 days. J) CXCR4 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. K-L) GL7 expression in GL7+ CD19+ GC-like B cell population and the percentage of CD83 + CD19 + GC B as a function of B cell seeding density in 10 μL PEG-MAL hydrogel, cultured for 4 days. ***P < 0.0001, **P < 0.001, *P < 0.05; 1 Way ANOVA with Tukey’s Test. Values are shown as mean ± SEM (n = 5). M-N) CD83 and CXCR4 expression level based on median fluorescence intensity (MFI) in CD83 + CD19 + B cell population following 4-day culture in RGD hydrogel with the addition of anti-CD40L antibody to block CD40 signaling at day 0 (D0) and day 2 (D2). Control group was prepared with no blocking performed (No Block). Statistical significance was tested based on p < 0.05 using 1-way ANOVA with Tukey’s test (N = 5; Mean ± S.E.M). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Journal: Biomaterials

Article Title: Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells

doi: 10.1016/j.biomaterials.2018.06.034

Figure Lengend Snippet: A) Schematic showing PEG-MAL hydrogels functionalized with REDV or RGD peptides and embedded with naïve B cells and 40LB stromal cells in the presence of soluble IL-4 cytokine. B) Phase contrast images show qualitative distribution of B cells in 2D co-cultures (left) and 3D immune tissues (right). C) Confocal images of 40LB stromal cells and B cells in 3D immune tissues. D) Role of integrin ligand and 40LB density on GC induction. Scatter plot represents median fluorescent intensity of GL7 in GL7+CD19+ GC B cells as a function of integrin ligand VCAM-1 (REDV) and vitronectin (RGD), and 40LB cell density (20,000 vs. 40,000 40LB cells per 10 μL hydrogel). N = 6; Mean ± S.E.M; **P < 0.005, *P < 0.05; 2-way ANOVA with Bonferroni correction. E) Effect of blocking CD40L on GC induction. Scatter plot represents percentage GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with RGD in the presence of anti-CD40L antibody added at various time points in culture. N = 5; Mean ± S.E.M; ***P < 0.0001; 1-way ANOVA with Tukey’s post-hoc correction. F) Temporal dependency of integrin ligand interaction on GC B cells. Relative percentages of cells were quantified for GL7+ CD19+ GC-like B cells following culture in hydrogel functionalized with either REDV (blue) or RGD (red) in the presence of anti-α4β1 antibody or Cilengitide anti-αvβ3 peptide) added at various time points in culture. GL7+ CD19 + percentage was normalized to the no inhibitor treatment. N = 6; Mean ± S.E.M; Statistical significance was tested based on p < 0.05 using 2-way ANOVA with Bonferroni correction. ***P < 0.0001, **P < 0.001. Control: No inhibitor. G) The percentage of CD83 + CD19 + B cells as a function of hydrogel volume. Immune tissues, encapsulating 40,000 B cells and 40,000 40LB cells, were cultured for 4 days in media containing 10 ng/mL IL-4. H) CD83 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. I) CD83 + CD19 + and CD83−CD19 + B cells as a function of hydrogel volume, cultured for 4 days. J) CXCR4 surface expression level in CD83 + CD19 + GC B cells as a function of hydrogel volume, cultured for 4 days. K-L) GL7 expression in GL7+ CD19+ GC-like B cell population and the percentage of CD83 + CD19 + GC B as a function of B cell seeding density in 10 μL PEG-MAL hydrogel, cultured for 4 days. ***P < 0.0001, **P < 0.001, *P < 0.05; 1 Way ANOVA with Tukey’s Test. Values are shown as mean ± SEM (n = 5). M-N) CD83 and CXCR4 expression level based on median fluorescence intensity (MFI) in CD83 + CD19 + B cell population following 4-day culture in RGD hydrogel with the addition of anti-CD40L antibody to block CD40 signaling at day 0 (D0) and day 2 (D2). Control group was prepared with no blocking performed (No Block). Statistical significance was tested based on p < 0.05 using 1-way ANOVA with Tukey’s test (N = 5; Mean ± S.E.M). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Integrin avb3-binding RGD peptide (G RGD SPC, >90% purity), scrambled peptide (G RDG SPC, >90% purity) integrin α4β1-binding REDV peptide (G REDV GC, >90% purity), and matrix metalloproteinases (MMP)-9 degradable VPM peptide (GCRD VPM SMRGGDRCG, >90% purity) were obtained from AAPPTec (Louisville, KY).

Techniques: Blocking Assay, Cell Culture, Expressing, Fluorescence

A) Confocal images of day 4 B cells from 2D co-cultures or 3D immune tissues functionalized with a specific peptide (REDV, RGD, or RDG). Cells were stained for IgM BCR and integrin β subunits on the surface of CD19 + B cells. Scale bar 5 μm. In all studies, immune tissues, encapsulating 40,000 B cells and 40,000 40LB cells, were cultured for 4 days in media containing 10 ng/mL IL-4. B) Schematic showing the BCR crosslinking inside the immune tissues with anti-IgM antibody as an antigen mimic. C) GL7 surface expression level in GL7+ CD19+ GC-like B cells with/without BCR crosslinking and specific integrin ligands. D-F) pBTK, pSYK, and pERK intracellular expression level (normalized to untreated control group in RGD) in CD19 + B cells. In all studies, anti-IgM concentration was either 0 μ μg/mL (indicated as −) or 5 μ μg/mL (indicated as +). Experiments were done with n = 5–7, presented as mean ± standard error (scatter plot only) with statistical significance indicated by p < 0.05 (***P < 0.0001, **P < 0.001). Statistical tests were performed using 1-way ANOVA with Tukey’s correction.

Journal: Biomaterials

Article Title: Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells

doi: 10.1016/j.biomaterials.2018.06.034

Figure Lengend Snippet: A) Confocal images of day 4 B cells from 2D co-cultures or 3D immune tissues functionalized with a specific peptide (REDV, RGD, or RDG). Cells were stained for IgM BCR and integrin β subunits on the surface of CD19 + B cells. Scale bar 5 μm. In all studies, immune tissues, encapsulating 40,000 B cells and 40,000 40LB cells, were cultured for 4 days in media containing 10 ng/mL IL-4. B) Schematic showing the BCR crosslinking inside the immune tissues with anti-IgM antibody as an antigen mimic. C) GL7 surface expression level in GL7+ CD19+ GC-like B cells with/without BCR crosslinking and specific integrin ligands. D-F) pBTK, pSYK, and pERK intracellular expression level (normalized to untreated control group in RGD) in CD19 + B cells. In all studies, anti-IgM concentration was either 0 μ μg/mL (indicated as −) or 5 μ μg/mL (indicated as +). Experiments were done with n = 5–7, presented as mean ± standard error (scatter plot only) with statistical significance indicated by p < 0.05 (***P < 0.0001, **P < 0.001). Statistical tests were performed using 1-way ANOVA with Tukey’s correction.

Article Snippet: Integrin avb3-binding RGD peptide (G RGD SPC, >90% purity), scrambled peptide (G RDG SPC, >90% purity) integrin α4β1-binding REDV peptide (G REDV GC, >90% purity), and matrix metalloproteinases (MMP)-9 degradable VPM peptide (GCRD VPM SMRGGDRCG, >90% purity) were obtained from AAPPTec (Louisville, KY).

Techniques: Staining, Cell Culture, Expressing, Concentration Assay

A) BCL6 intracellular expression level in GL7+ CD19+ GC-like B cells with or without BCR crosslinking and specific integrin ligands. B) The percentage of EZH2+ GL7+ CD19+ GC-like B cells with or without BCR crosslinking and specific integrin ligands. C) EZH2 intracellular expression level (normalized to untreated control group) in EZH2+ GL7+ CD19+ GC-like B cells with or without BCR crosslinking and specific integrin ligands. D-E) IRF4 intracellular expression level and CD138 expression level in immune tissue-derived B cells. In all studies, anti-IgM concentration was either 0 μg/mL (indicated as −) or 5 μg/mL (indicated as +). Experiments were done with N = 5–7, presented as Mean ± Standard Error (scatter plot only) with statistical significance indicated by p < 0.05 (***P < 0.0001, **P < 0.001, *P < 0.05). Statistical tests were performed using unpaired student t-test for (E) and 1-way ANOVA with Tukey’s correction for (A–D).

Journal: Biomaterials

Article Title: Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells

doi: 10.1016/j.biomaterials.2018.06.034

Figure Lengend Snippet: A) BCL6 intracellular expression level in GL7+ CD19+ GC-like B cells with or without BCR crosslinking and specific integrin ligands. B) The percentage of EZH2+ GL7+ CD19+ GC-like B cells with or without BCR crosslinking and specific integrin ligands. C) EZH2 intracellular expression level (normalized to untreated control group) in EZH2+ GL7+ CD19+ GC-like B cells with or without BCR crosslinking and specific integrin ligands. D-E) IRF4 intracellular expression level and CD138 expression level in immune tissue-derived B cells. In all studies, anti-IgM concentration was either 0 μg/mL (indicated as −) or 5 μg/mL (indicated as +). Experiments were done with N = 5–7, presented as Mean ± Standard Error (scatter plot only) with statistical significance indicated by p < 0.05 (***P < 0.0001, **P < 0.001, *P < 0.05). Statistical tests were performed using unpaired student t-test for (E) and 1-way ANOVA with Tukey’s correction for (A–D).

Article Snippet: Integrin avb3-binding RGD peptide (G RGD SPC, >90% purity), scrambled peptide (G RDG SPC, >90% purity) integrin α4β1-binding REDV peptide (G REDV GC, >90% purity), and matrix metalloproteinases (MMP)-9 degradable VPM peptide (GCRD VPM SMRGGDRCG, >90% purity) were obtained from AAPPTec (Louisville, KY).

Techniques: Expressing, Derivative Assay, Concentration Assay